Nyxoah SA
Develops hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).
NYXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974358906
- LEI:
- 5493002O1ESKZ18OXR80
- Country:
- Belgium
- Address:
- Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
- Website:
- https://www.nyxoah.com/
- Sector:
- Manufacturing
Description
Nyxoah SA is a medical technology company focused on the development and commercialization of solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, a hypoglossal neurostimulation (HNS) therapy designed for patients with moderate to severe OSA. The system features a patient-centered, leadless, and battery-free implantable stimulator. It functions by providing bilateral stimulation to the hypoglossal nerve, which controls tongue muscles, to maintain an open airway during sleep.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-13 07:00 |
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating R…
|
English | 56.4 KB | ||
| 2025-02-20 07:05 |
Nyxoah Announces Commercial Launch of Genio Breakthrough Therapy in the Middle …
|
English | 10.8 KB | ||
| 2025-02-19 07:05 |
Nyxoah Announces Commercial Launch of Genio Breakthrough Therapy in the Middle …
|
English | 10.8 KB | ||
| 2025-01-20 22:30 |
2025 01 20 PR Transparency notification 2025 01 (BlackRock) (ENG).pdf
|
English | 181.1 KB | ||
| 2025-01-20 22:30 |
2025 01 20 PR Transparency notification 2025 01 (BlackRock) (FR).pdf
|
French | 181.3 KB | ||
| 2025-01-20 22:30 |
2025 01 20 PR Transparency notification 2025 01 (BlackRock) (ENG).pdf
|
English | 181.1 KB | ||
| 2025-01-20 22:30 |
2025 01 20 PR Transparency notification 2025 01 (BlackRock) (FR).pdf
|
French | 181.3 KB | ||
| 2024-12-20 22:30 |
2024 12 20 PR Transparency notification 2024 12 (BlackRock) (ENG).pdf
|
English | 620.6 KB | ||
| 2024-12-20 22:30 |
2024 12 20 PR Transparency notification 2024 12 (BlackRock) (FR).pdf
|
French | 624.8 KB | ||
| 2024-12-19 15:00 |
Nyxoah - SSM 2024 - Minutes - FR - signed.pdf
|
French | 552.8 KB | ||
| 2024-12-14 08:05 |
Nyxoah Announces Commercial Launch of Genio Innovative Therapy in England
|
English | 11.7 KB | ||
| 2024-12-13 08:05 |
Nyxoah Announces Commercial Launch of Genio Innovative Therapy in England
|
English | 11.7 KB | ||
| 2024-11-27 22:30 |
2024 11 27 - Press release - Number of shares (ENG).pdf
|
English | 136.4 KB | ||
| 2024-11-27 22:30 |
2024 11 27 - Press release - Number of shares (FR).pdf
|
French | 135.7 KB | ||
| 2024-11-19 07:00 |
Nyxoah - SSM 2024 - Proxy form - ENG FR.pdf
|
French | 281.6 KB |
Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nyxoah SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nyxoah SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-19 | Laurette Renard | Close relation | Sell | 5,000 | 39,000.00 EUR |
| 2024-09-05 | Hambrecht Jürgen | Board | Sell | 980,000 | 6,840,400.00 EUR |
| 2024-09-05 | JH Capital GmbH | Close relation | Buy | 980,000 | 6,840,400.00 EUR |
| 2024-01-25 | Tompkins Patrick | Executive member | Buy | 2,000 | 18,020.00 USD |
| 2023-12-28 | Onkelinx Bruno | Executive member | Buy | 470 | 2,035.10 EUR |
| 2023-08-18 | Moreau Loïc | Executive member | Buy | 6,427 | 48,416.52 EUR |
| 2023-08-14 | Moreau Loïc | Executive member | Buy | 3,800 | 28,697.60 EUR |
| 2023-08-11 | Moreau Loïc | Executive member | Buy | 3,000 | 21,957.60 EUR |
| 2023-07-04 | Wildman Ventures LLC | Board | Buy | 25,000 | N/A |
| 2023-07-02 | Gianello Pierre | Board | Buy | 25,000 | N/A |
Peer Companies
